Home Blog of Signal Transduction PI3K/Akt/mTOR DNA-PK

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

DNA-PK

Drug Repositioning Identifies Six Drug Candidates for Systemic Autoimmune Diseases by Integrative Analyses of Transcriptomes from Scleroderma, Systemic Lupus Erythematosus, and Sjogren's Syndrome

0 views | Jan 18 2024

This study utilizing transcriptome data and bioinformatic analysis identified common gene signatures across systemic autoimmune diseases, leading to the discovery of six potential small molecule drug candidates through drug repositioning, shedding light on novel therapeutic avenues for these conditions. [Read the Full Post]

PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, relieves airway hyperresponsiveness, mucus hypersecretion and inflammation in a murine asthma model

218 views | Jan 14 2024

PP121, a dual tyrosine and phosphoinositide kinase inhibitor, demonstrates promising anti-contractile and anti-inflammatory effects in asthma treatment, suggesting its potential as a novel therapeutic compound for managing the condition. [Read the Full Post]

Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization

88 views | Nov 13 2023

The Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) is a phase II platform trial that employs genomic profiling and adaptive randomization to evaluate novel therapies for glioblastoma, with abemaciclib and neratinib showing improved progression-free survival compared to the control arm, although none of the experimental therapies demonstrated a significant overall survival benefit. [Read the Full Post]

Chemical inhibition of DNA-PKcs impairs the activation and cytotoxicity of CD4+ helper and CD8+ effector T cells

133 views | Aug 31 2023

Inhibition of DNA-PKcs using small-molecule inhibitors abrogates T cell activation, impairs metabolic pathways and proliferation, and reduces cytotoxicity, highlighting its potential as a therapeutic target for immune modulation in autoimmune diseases, immune-related disorders, and cancer. [Read the Full Post]

Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia

77 views | Aug 12 2023

This study demonstrates that targeting DNA-PK in KIT mutant acute myeloid leukemia (AML) cells, in combination with inhibitors of KIT signaling, shows synergistic effects and holds promise as a therapeutic strategy for this aggressive form of AML. [Read the Full Post]

Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53-Mutant Cancers

81 views | Aug 12 2023

Combining the DNA-PK/NHEJ inhibitor peposertib with the POLθ/MMEJ inhibitor novobiocin provides a rational treatment strategy for TP53-mutant solid tumors, resulting in synthetic lethality and potential therapeutic efficacy. [Read the Full Post]

Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing

73 views | Jul 28 2023

The study found that mTOR and Chk1 pathway inhibitors showed promising efficacy in established and patient-derived cell models of pleural mesothelioma, suggesting their potential as novel treatment strategies. [Read the Full Post]

Anal Cancer Prevention Through the Topical Use of Single or Dual PI3K/mTOR Inhibitors

108 views | Jul 28 2023

In this study, topical inhibition of the mTOR and/or PI3K pathways demonstrated promising results in increasing tumor-free survival and reducing squamous cell carcinoma in mice with anal dysplasia and anal cancer. [Read the Full Post]

THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors

68 views | Jul 14 2023

Combining the CDK12 inhibitor THZ531 with DNA repair inhibitors such as Olaparib holds potential as an effective therapeutic approach for multiple myeloma by inducing synergistic cell death and reducing tumor burden. [Read the Full Post]

A Cell System-Assisted Strategy for Evaluating the Natural Antioxidant-Induced Double-Stranded DNA Break (DSB) Style

149 views | Apr 11 2023

Researchers evaluated whether natural antioxidants induce DNA damage using gene-knockout cell lines and found that sulforaphane induces single-strand breaks or DNA strand crosslinks, quercetin induces double-strand breaks, while resveratrol exerts cytotoxic effects other than DNA damage, and the mechanisms through which kaempferol and genistein induce DNA damage remain unknown. [Read the Full Post]